Bioheart Inc. (BHRT) 0.0124 $BHRT
Bioheart Announces Completion of First Stem Cell Training in Australia
ACCESSWIRE - Mon Dec 22, 9:09AM CST
SUNRISE, FL / ACCESSWIRE / December 22, 2014 / Bioheart, Inc. (BHRT.OB), a biotechnology company focused on the discovery, development and, subject to United States regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, announces completion of the first stem cell training course to bring regenerative therapies to Australia. (www.usstemcelltraining.com)
Bioheart Announces Joint Venture In Nigeria
ACCESSWIRE - Thu Dec 18, 7:01AM CST
SUNRISE, FL / ACCESSWIRE / December 18, 2014 / Bioheart, Inc. (OTCQB:BHRT), a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, announced today that it has entered into a joint venture with Dr. Prosper Igboeli of Nigeria.
Bioheart Announces Expansion Of Clinical Study For Degenerative Disc Disease
ACCESSWIRE - Mon Nov 17, 7:01AM CST
Untitled Document
Bioheart Announces First Intracoronary Implantation of Adipose Stem Cells in Azerbaijan
ACCESSWIRE - Wed Nov 12, 10:22AM CST
SUNRISE, FL / ACCESSWIRE / November 12, 2014 / Bioheart, Inc. (OTCQB:BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced today that the first successful intracoronary implantation of autologous adipose-derived stem cell (ADSC) was performed to a 70 year-old male patient with ischemic cardiomyopathy by Emrah Anar MD (Chief of Cardiology and Cardiovascular Surgery) in Baku (Azerbaijan) Cardiac Center of Central Military Hospital.
Miami Dade College Names Bioheart CEO, Mike Tomas, to Board of Advisors for New Idea Center
Marketwired - Thu Oct 30, 7:02AM CDT
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that Mike Tomas, President and CEO, will sit on the board of advisors for Miami Dade College's new Idea Center which will serve as Miami Dade College's hub for entrepreneurship for its 165,000 students. The Idea Center will include a venture incubator, called CREATE, with programming and resources to help nurture and accelerate the entrepreneurial ideas and ventures of students.
Bioheart, Inc. Completes Financing With Magna
Marketwired - Fri Oct 24, 3:00PM CDT
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, a Florida corporation, is pleased to announce the closing of a common stock purchase agreement for a $3 million Equity Enhancement Program ("EEP"
with a Magna affiliate fund, Magna Equities II, LLC (the "Investor" . The EEP allows, but does not obligate the Company to issue and sell up to $3,000,000 worth of the Company's common stock to the Investor from time to time, over the 24-month term of the purchase agreement.
Bioheart Announces Partnership in Colombia
Marketwired - Wed Oct 15, 7:05AM CDT
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and, subject to United States regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, announces partnership to bring Bioheart regenerative therapies to Colombia.
Bioheart Announces Positive 12 Month Preliminary Data From Phase I Angel Trial
Marketwired - Mon Oct 13, 7:02AM CDT
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, released today preliminary 12 month data from its phase I ANGEL Trial. Fully funded by Bioheart, the trial is being conducted in Mexico at the Hospital Angeles in conjunction with the Regenerative Medicine Institute (RMI).
Bioheart Announces Successful Grand Opening of Facility in South Africa
Marketwire - Wed Sep 24, 7:01AM CDT
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and, subject to United States regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, announces a successful grand opening of the laboratory and clinic in South Africa.
Bioheart Announces Grand Opening of Facility in South Africa
Marketwire - Tue Sep 16, 7:03AM CDT
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, announces the grand opening the laboratory and clinic in South Africa.
Bioheart Releases Q2 Financial Information Showing Growth
Marketwire - Thu Aug 07, 7:04AM CDT
Bioheart, Inc. (OTCQB: BHRT) released today financial information based on results from Q2 2014. The financial data shows that Bioheart has grown in product revenues, increased income, reduced debt, and further strengthened the financial standing of the company.
Bioheart Announces World's First Combination Stem Cell Treatment
Marketwire - Thu Jul 24, 7:23AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that it has completed the world's first combination stem cell treatment with Magnum Cell Therapies (Magnum) in Honduras. A patient with congestive heart failure has been treated with a combination of AdipoCell(TM) or adipose derived stem cells and MyoCell(R) or muscle derived stem cells. AdipoCell may help to promote angiogenesis or new blood vessel formation in ischemic tissue while MyoCell may help to promote myogenesis or new muscle formation. The cells were delivered directly into the damaged areas of the heart using the MyoCath(R) Catheter.
Bioheart Announces Grand Opening of Magnum Cell Therapies
Marketwire - Wed Jul 16, 7:02AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that it will participate in the grand opening event of Magnum Cell Therapies (Magnum) in Honduras during the week of July 21st. Bioheart has previously announced the joint venture with Magnum and the goal to bring regenerative therapies to patients in South America.
Bioheart Announces Clinical Trials in India
Marketwire - Mon Jul 07, 7:01AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that they have begun two clinical trials in India including the first ever combination stem cell trial in the world. The first cardiac patient has successfully been enrolled and treated in India using AdipoCell(TM) or adipose derived stem cells. The second trial will involve the combination of AdipoCell and MyoCell(R) or muscle derived stem cells for congestive heart failure patients. AdipoCell may help to promote angiogenesis or new blood vessel formation in ischemic tissue while MyoCell may help to promote myogenesis or new muscle formation.
Bioheart Announces Joint Venture in South Africa
Marketwire - Tue Jun 24, 7:01AM CDT
Bioheart, Inc. (OTCBB: BHRT), a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, announced today that it has entered into a joint venture with Dr. Walter Bell of South Africa.
Bioheart Announces Completion of First Stem Cell Training in Australia
ACCESSWIRE - Mon Dec 22, 9:09AM CST
SUNRISE, FL / ACCESSWIRE / December 22, 2014 / Bioheart, Inc. (BHRT.OB), a biotechnology company focused on the discovery, development and, subject to United States regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, announces completion of the first stem cell training course to bring regenerative therapies to Australia. (www.usstemcelltraining.com)
Bioheart Announces Joint Venture In Nigeria
ACCESSWIRE - Thu Dec 18, 7:01AM CST
SUNRISE, FL / ACCESSWIRE / December 18, 2014 / Bioheart, Inc. (OTCQB:BHRT), a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, announced today that it has entered into a joint venture with Dr. Prosper Igboeli of Nigeria.
Bioheart Announces Expansion Of Clinical Study For Degenerative Disc Disease
ACCESSWIRE - Mon Nov 17, 7:01AM CST
Untitled Document
Bioheart Announces First Intracoronary Implantation of Adipose Stem Cells in Azerbaijan
ACCESSWIRE - Wed Nov 12, 10:22AM CST
SUNRISE, FL / ACCESSWIRE / November 12, 2014 / Bioheart, Inc. (OTCQB:BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced today that the first successful intracoronary implantation of autologous adipose-derived stem cell (ADSC) was performed to a 70 year-old male patient with ischemic cardiomyopathy by Emrah Anar MD (Chief of Cardiology and Cardiovascular Surgery) in Baku (Azerbaijan) Cardiac Center of Central Military Hospital.
Miami Dade College Names Bioheart CEO, Mike Tomas, to Board of Advisors for New Idea Center
Marketwired - Thu Oct 30, 7:02AM CDT
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that Mike Tomas, President and CEO, will sit on the board of advisors for Miami Dade College's new Idea Center which will serve as Miami Dade College's hub for entrepreneurship for its 165,000 students. The Idea Center will include a venture incubator, called CREATE, with programming and resources to help nurture and accelerate the entrepreneurial ideas and ventures of students.
Bioheart, Inc. Completes Financing With Magna
Marketwired - Fri Oct 24, 3:00PM CDT
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, a Florida corporation, is pleased to announce the closing of a common stock purchase agreement for a $3 million Equity Enhancement Program ("EEP"
with a Magna affiliate fund, Magna Equities II, LLC (the "Investor" . The EEP allows, but does not obligate the Company to issue and sell up to $3,000,000 worth of the Company's common stock to the Investor from time to time, over the 24-month term of the purchase agreement. Bioheart Announces Partnership in Colombia
Marketwired - Wed Oct 15, 7:05AM CDT
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and, subject to United States regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, announces partnership to bring Bioheart regenerative therapies to Colombia.
Bioheart Announces Positive 12 Month Preliminary Data From Phase I Angel Trial
Marketwired - Mon Oct 13, 7:02AM CDT
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, released today preliminary 12 month data from its phase I ANGEL Trial. Fully funded by Bioheart, the trial is being conducted in Mexico at the Hospital Angeles in conjunction with the Regenerative Medicine Institute (RMI).
Bioheart Announces Successful Grand Opening of Facility in South Africa
Marketwire - Wed Sep 24, 7:01AM CDT
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and, subject to United States regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, announces a successful grand opening of the laboratory and clinic in South Africa.
Bioheart Announces Grand Opening of Facility in South Africa
Marketwire - Tue Sep 16, 7:03AM CDT
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, announces the grand opening the laboratory and clinic in South Africa.
Bioheart Releases Q2 Financial Information Showing Growth
Marketwire - Thu Aug 07, 7:04AM CDT
Bioheart, Inc. (OTCQB: BHRT) released today financial information based on results from Q2 2014. The financial data shows that Bioheart has grown in product revenues, increased income, reduced debt, and further strengthened the financial standing of the company.
Bioheart Announces World's First Combination Stem Cell Treatment
Marketwire - Thu Jul 24, 7:23AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that it has completed the world's first combination stem cell treatment with Magnum Cell Therapies (Magnum) in Honduras. A patient with congestive heart failure has been treated with a combination of AdipoCell(TM) or adipose derived stem cells and MyoCell(R) or muscle derived stem cells. AdipoCell may help to promote angiogenesis or new blood vessel formation in ischemic tissue while MyoCell may help to promote myogenesis or new muscle formation. The cells were delivered directly into the damaged areas of the heart using the MyoCath(R) Catheter.
Bioheart Announces Grand Opening of Magnum Cell Therapies
Marketwire - Wed Jul 16, 7:02AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that it will participate in the grand opening event of Magnum Cell Therapies (Magnum) in Honduras during the week of July 21st. Bioheart has previously announced the joint venture with Magnum and the goal to bring regenerative therapies to patients in South America.
Bioheart Announces Clinical Trials in India
Marketwire - Mon Jul 07, 7:01AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that they have begun two clinical trials in India including the first ever combination stem cell trial in the world. The first cardiac patient has successfully been enrolled and treated in India using AdipoCell(TM) or adipose derived stem cells. The second trial will involve the combination of AdipoCell and MyoCell(R) or muscle derived stem cells for congestive heart failure patients. AdipoCell may help to promote angiogenesis or new blood vessel formation in ischemic tissue while MyoCell may help to promote myogenesis or new muscle formation.
Bioheart Announces Joint Venture in South Africa
Marketwire - Tue Jun 24, 7:01AM CDT
Bioheart, Inc. (OTCBB: BHRT), a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, announced today that it has entered into a joint venture with Dr. Walter Bell of South Africa.
